Equities
  • Price (MXN)2,703.30
  • Today's Change-11.70 / -0.43%
  • Shares traded128.00
  • 1 Year change--
  • Beta1.3743
Data delayed at least 20 minutes, as of Aug 13 2020 20:56 BST.
More ▼

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

  • Revenue in USD (TTM)7.53bn
  • Net income in USD749.00m
  • Incorporated1996
  • Employees47.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Mid America Clinical Laboratories LLCDeal completed23 Jun 202023 Jun 2020Deal completed10.77%--
Memorial Hermann Healthcare System-Laboratories & Service CentersDeal completed27 Jan 202027 Jan 2020Deal completed12.95%--
Blueprint Genetics OyDeal completed22 Jan 202022 Jan 2020Deal completed13.42%--
Data delayed at least 15 minutes, as of Aug 13 2020 21:10 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.